{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:04:30Z","timestamp":1789535070132,"version":"build-2803163510"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic peripheral neuropathy (DPN) is a leading cause of neuropathic pain, disability and lower-limb amputation, and the pharmacological options currently available do little to reverse established nerve injury. Compound traditional Chinese medicine preparations that activate blood circulation and unblock the collaterals have shown promise as add-on therapy to neurotrophic treatment, improving nerve conduction and relieving symptoms, but head-to-head comparisons between individual formulas are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, the Cochrane Library, CNKI, Wanfang and other databases were searched to July 2026 for randomised controlled trials comparing a blood-activating, collateral-unblocking formula plus mecobalamin with mecobalamin alone in adults with type 2 diabetes and peripheral neuropathy. The primary outcome was the Toronto Clinical Scoring System (TCSS); secondary outcomes were motor and sensory conduction velocity (MCV, SCV) of the median and common peroneal nerves, together with adverse events. Mean differences (MD) and 95% credible intervals were estimated in a Bayesian random-effects model, and ranking distributions were summarised as the surface under the cumulative ranking curve (SUCRA). Risk of bias was assessed with RoB 2 and certainty of evidence with CINeMA (Confidence in Network Meta-Analysis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nineteen randomised controlled trials (2,090 participants) were included. All were conducted in China, and most nodes were informed by a single trial. Relative to mecobalamin alone, most add-on regimens improved TCSS and nerve conduction velocity. Credible intervals excluded zero for 9 of 12 formulas for TCSS, 7 of 14 for median nerve MCV, 3 of 14 for median nerve SCV, 5 of 14 for peroneal nerve MCV and 8 of 9 for peroneal nerve SCV. By SUCRA, Yiqi Huashi Tongbi Formula ranked first for TCSS (90.3%; MD -3.49, 95% CrI -5.17 to -1.81), Shengyang Sanhuo Decoction for median nerve MCV (85.6%; MD 4.16, 95% CrI 1.58 to 6.78), Xiaoma Zhitong Capsule for median nerve SCV (84.4%; MD 4.19, 95% CrI 0.88 to 7.58), Modified Buyang Huanwu Decoction for peroneal nerve MCV (79.2%; MD 3.78, 95% CrI 0.83 to 6.72) and Jiangtang Tongluo Tablet for peroneal nerve SCV (95.2%; MD 4.08, 95% CrI 2.38 to 5.78). Eight of the 19 trials made no mention of adverse-event monitoring, and none reported numerical laboratory safety data. The available information is insufficient to evaluate the safety of these add-on regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adding blood-activating, collateral-unblocking traditional Chinese medicine to mecobalamin was associated with improvement in TCSS and in nerve conduction velocity in patients with DPN. Certainty of evidence was very low for every comparison, however, and prediction intervals crossed the line of no effect for three outcomes, indicating that the direction of effect could change in a new study. The rankings are exploratory and hypothesis-generating: they are not a sufficient basis for inferring definite clinical efficacy or for choosing a formula for an individual patient, and they require confirmation in adequately powered, prospectively registered, blinded multicentre head-to-head trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD42025123604.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1888494","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:31:38Z","timestamp":1789533098000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Blood-activating and collateral-unblocking traditional Chinese medicine formulas combined with mecobalamin for peripheral neuropathy in type 2 diabetes: a systematic review and Bayesian network meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Zijian","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowen","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Nursing, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luying","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Endocrinology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Department of Nephrology, Fangshan Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1303","article-title":"Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments","volume":"33","author":"Tesfaye","year":"2010","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2042","article-title":"Diabetic neuropathy: a position statement by the American Diabetes Association","volume":"40","author":"Pop-Busui","year":"2017","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.117959","article-title":"Exploring the role of exosomes in diabetic neuropathy: from molecular mechanisms to therapeutic potential","volume":"185","author":"Tajabadi","year":"2025","journal-title":"BioMed Pharmacother"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3702","article-title":"Prevalence and risk factors of diabetic peripheral neuropathy: a population-based cross-sectional study in China","volume":"39","author":"Wang","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1265372","article-title":"Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment","volume":"14","author":"Zhu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910785","article-title":"Unveiling the role of Schwann cell plasticity in the pathogenesis of diabetic peripheral neuropathy","volume":"25","author":"Abd Razak","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1042\/cs0900183","article-title":"Rheological and microvascular parameters in diabetic peripheral neuropathy","volume":"90","author":"Young","year":"1996","journal-title":"Clin Sci (Lond)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/2042018819826890","article-title":"Diagnosing and managing diabetic somatic and autonomic neuropathy","volume":"10","author":"Azmi","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2174\/1573399817666210707112413","article-title":"The treatment of painful diabetic neuropathy","volume":"18","author":"Sloan","year":"2022","journal-title":"Curr Diabetes Rev"},{"key":"B11","first-page":"496","article-title":"National guidelines for the diagnosis and treatment of diabetic neuropathy in primary care (2024 edition)","volume":"16","year":"2024","journal-title":"Chin J Diabetes"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2020.0068","article-title":"Efficacy and safety of mecobalamin on peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Sawangjit","year":"2020","journal-title":"J Altern Complement Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2012.07.034","article-title":"Chinese herbal medicine in treatment of diabetic peripheral neuropathy: a systematic review and meta-analysis","volume":"143","author":"Xu","year":"2012","journal-title":"J Ethnopharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.16025\/j.1674-1307.2022.11.001","article-title":"Review of research on treating diabetic peripheral neuropathy from collateral disease theory","volume":"41","author":"Zhang","year":"2022","journal-title":"Beijing J Tradit Chin Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B16","volume-title":"Pharmacopoeia of the People's Republic of China","year":"2020"},{"key":"B17","volume-title":"International Nonproprietary Names (Inn) for Pharmaceutical Substances","year":"2004"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.11.2048","article-title":"Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy","volume":"25","author":"Bril","year":"2002","journal-title":"Diabetes Care"},{"key":"B19","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 6.4","author":"Higgins","year":"2023"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.13422\/j.cnki.syfjx.2009.01.003","article-title":"Clinical study on Tangmaining Capsules in the treatment of diabetic peripheral neuropathy","volume":"15","author":"Shen","year":"2009","journal-title":"Chin J Exp Tradit Med Form"},{"key":"B22","doi-asserted-by":"publisher","first-page":"998","DOI":"10.19945\/j.cnki.issn.1006-3250.2012.09.030","article-title":"Clinical observation of diabetic peripheral neuropathy by the interference of Liver-Nourishing, Endogenous Wind-Stopping and Collateral-Unblocking Decoction","volume":"18","author":"Gao","year":"2012","journal-title":"Chin J Basic Med Tradit Chin Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.13422\/j.cnki.syfjx.2014220189","article-title":"Improvement effect and mechanism of Xiaoma Zhitong Capsule on nerve conduction velocity in patients with diabetic peripheral neuropathy","volume":"20","author":"Zhou","year":"2014","journal-title":"Chin J Exp Tradit Med Form"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.13863\/j.issn1001-4454.2015.12.050","article-title":"Clinical observation of Modified Guizhi Shaoyao Zhimu Decoction in treating diabetic peripheral neuropathy with Yang deficiency and intermingled dampness-blood stasis syndrome","volume":"38","author":"Song","year":"2015","journal-title":"J Chin Med Mater"},{"key":"B25","article-title":"Clinical observation of Modified Huangqi Guizhi Wuwu Decoction in treating elderly patients with type 2 diabetic peripheral neuropathy","volume":"55","author":"Liu","year":"2015","journal-title":"Shandong Med J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.13193\/j.issn.1673-7717.2017.03.042","article-title":"Clinical observation on the superior efficacy of \"Danggui Sini Decoction\" in treating diabetic peripheral neuropathy with cold coagulation and blood stasis syndrome","volume":"35","author":"Wang","year":"2017","journal-title":"Chin Arch Tradit Chin Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.13429\/j.cnki.cjcr.2017.11.036","article-title":"Clinical efficacy of Yiqi Huoxue Formula in the treatment of diabetic peripheral neuropathy","volume":"30","author":"Fang","year":"2017","journal-title":"Chin J Clin Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.16025\/j.1674-1307.2018.08.027","article-title":"Clinical observation of Jiangtang Tongluo Tablets in treating 43 cases of diabetic peripheral neuropathy with Qi deficiency and blood stasis syndrome","volume":"37","author":"Zhang","year":"2018","journal-title":"Beijing J Tradit Chin Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.13422\/j.cnki.syfjx.20191527","article-title":"Effect of Modified Buyang Huanwu Decoction on serum procollagen N-terminal peptide (PNT) and insulin-like growth factor-1 (IGF-1) levels in patients with diabetic peripheral neuropathy","volume":"25","author":"Pei","year":"2019","journal-title":"Chin J Exp Tradit Med Form"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.13193\/j.issn.1673-7717.2019.11.045","article-title":"Application of Danggui Sini Decoction in diabetic peripheral neuropathy and its effects on neuroelectrophysiological parameters","volume":"37","author":"Zhao","year":"2019","journal-title":"Chin Arch Tradit Chin Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.13412\/j.cnki.zyyl.2020.04.024","article-title":"Clinical study on Huoluo Zhixiao Formula in the intervention of diabetic peripheral neuropathy","volume":"36","author":"Zhi","year":"2020","journal-title":"Pharmacol Clin Chin Mater Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.13729\/j.issn.1671-7813.Z20200230","article-title":"Efficacy analysis of Yiqi Tongluo Huoxue Decoction combined with Western medicine in treating diabetic peripheral neuropathy with Qi deficiency and blood stasis syndrome","volume":"34","author":"Bao","year":"2020","journal-title":"J Pract Tradit Chin Intern Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.19378\/j.issn.1003-9783.2021.05.018","article-title":"Efficacy of Buqi Tongluo Capsule as adjuvant therapy for diabetic peripheral neuropathy and its effects on serum levels of malondialdehyde (MDA), total antioxidant capacity (T-AOC) and superoxide dismutase (SOD)","volume":"32","author":"Huang","year":"2021","journal-title":"Chin J New Drugs Clin Rem"},{"key":"B34","article-title":"Efficacy of using Shengyang Sanhuo Decoction in the treatment of diabetic peripheral neuropathy and its influence on nerve conduction velocity and inflammatory factors","volume":"41","author":"Zhu","year":"2023","journal-title":"J Sichuan Tradit Chin Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.13192\/j.issn.1000-1719.2024.04.025","article-title":"Yiqi Huashi Tongbi Recipe in treating diabetes peripheral neuropathy of qi deficiency and dampness stagnation","author":"Lei","year":"2024","journal-title":"Liaoning J Tradit Chin Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.13193\/j.issn.1673-7717.2025.08.041","article-title":"Effect of Huangqi Guizhi Wuwu Decoction on miR-146a\/MyD88\/I\u03baB signaling pathway in patients with diabetic peripheral neuropathy","volume":"43","author":"Jia","year":"2025","journal-title":"Chin Arch Tradit Chin Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.13359\/j.cnki.gzxbtcm.2025.01.013","article-title":"Effect of Modified Buyang Huanwu Decoction on serum fibroblast growth factor 21 (FGF21), 25-hydroxyvitamin D [25(OH)D], endothelin-1 (ET-1) levels and hypercoagulable state in patients with type 2 diabetic peripheral neuropathy of Qi deficiency and blood stasis syndrome","volume":"42","author":"Deng","year":"2025","journal-title":"J Guangzhou Univ Tradit Chin Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70045","article-title":"TangBi Formula for painful diabetic distal symmetric polyneuropathy: a multicenter, randomized, double-blind, placebo-controlled and parallel-group trial","volume":"17","author":"Zhao","year":"2025","journal-title":"J Diabetes"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2026.121754","article-title":"Efficacy and safety of Mudan granules for treatment of diabetic peripheral neuropathy: a multicenter, double-blind, placebo-controlled, randomized, clinical trial","volume":"368","author":"Jin","year":"2026","journal-title":"J Ethnopharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.12.9.649","article-title":"Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy","volume":"12","author":"Dyck","year":"1989","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1888494\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:32:10Z","timestamp":1789533130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1888494\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":40,"alternative-id":["10.3389\/fendo.2026.1888494"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1888494","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1888494"}}